The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Thu, 27th May 2021 16:06

Friday 28 May 
AG Barr PLCAGM
Agronomics LtdGM re fundraising
AIQ LtdAGM
Aseana Properties LtdGM re future of company
Ebiquity PLCAGM
HSBC Holdings PLCAGM
Minoan Group PLCAGM
Real Estate Investors PLCAGM
Reckitt Benckiser Group PLCAGM
Rotala PLCAGM
Tekcapital PLCAGM
Wameja LtdAGM
Monday 31 May 
no events scheduled 
Tuesday 1 June 
Churchill China PLCAGM
North American Income Trust PLCAGM
Wednesday 2 June 
Arrow Global Group PLCAGM
Everyman Media Group PLCAGM
Futura Medical PLCGM re fundraise
Gaming Realms PLCAGM
Gem Diamonds LtdAGM
GYG PLCAGM
Jersey Oil & Gas PLCAGM
Manx Financial Group PLCAGM
Pennant International Group PLCAGM
Surface Transforms PLCAGM
Tern PLCGM re authority to issue shares
Thursday 3 June 
Camellia PLCAGM
CentralNic Group PLCAGM
Checkit PLCAGM
Destiny Pharma PLCAGM
Flowtech Fluidpower PLCAGM
i3 Energy PLCGM re share capital reduction
Informa PLCAGM
Kazera Global PLCAGM
Menhaden PLCAGM
Michelmersh Brick Holdings PLCAGM
NetScientific PLCAGM
PageGroup PLCAGM
Pebble Group PLCAGM
Tissue Regenix Group PLCAGM
  
Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2021 20:37

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:25

Destiny Pharma upbeat on recent study into mupirocin alternative

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent "strong support" for the potential of its 'XF-73' nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.

Read more
27 Sep 2021 10:58

IN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project

IN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project

Read more
27 Sep 2021 10:10

Destiny Pharma's China partner starts new XF-73 programme

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Monday that its China regional partner and investor, China Medical System Holdings (CMS), is establishing a new programme with 'XF-73' targeting the prevention and treatment of superficial skin infections caused by bacteria.

Read more
9 Sep 2021 11:33

EARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black

EARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black

Read more
2 Sep 2021 14:55

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Aug 2021 11:39

TRADING UPDATES: Brickability buys Leadcraft; Aquis has record July

TRADING UPDATES: Brickability buys Leadcraft; Aquis has record July

Read more
2 Aug 2021 11:34

Destiny Pharma reports positive secondary data on 'XF-73'

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced additional, "strong" data from its recent phase 2b clinical trial on Monday.

Read more
6 Jul 2021 20:38

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

Read more
6 Jul 2021 10:35

Destiny Pharma inks research deal with US Veterans' Affairs

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced a cooperative research and development agreement with the US Department of Veterans' Affairs on Tuesday, to support studies focusing on identifying new attributes for 'NTCD-M3' - a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections in the gut.

Read more
10 Jun 2021 19:46

TRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing

TRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing

Read more
7 Jun 2021 17:59

TRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent

TRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
2 Jun 2021 10:26

Destiny Pharma reports positive progress on lead clinical programme

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive progress with its lead clinical programme, 'NTCD-M3', on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.